Beta Drugs gets NSE nod to migrate from SME EMERGE to Main Board

Capital Market Events View source PDF Explain this filing

BETA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹1676.50

prior close

₹1660.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+0.3% vs market

Pharmaceuticals peers, median of 157sector-0.1%+0.3% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.2

15m

+1.1

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2-0.1+0.3-0.1+0.3

Next day

-0.6-0.2-0.4-0.4-0.2

-1.5+0.4-1.9-0.3-1.2

-1.3-0.4-0.9-1.0-0.3

-1.0-0.6-0.5-1.4+0.3

-3.1-0.9-2.2-1.5-1.5

-4.3-3.0-1.3-3.2-1.1

15d

+0.1-3.9+4.0-3.4+3.6

-4.9-4.8-0.0-4.0-0.8

-4.6-7.8+3.2-6.9+2.3

-17.7-7.2-10.4-8.5-9.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beta Drugs Limited has received in-principle approval from NSE to migrate trading of its equity shares from the SME EMERGE platform to the NSE Main Board. The approval covers about 1.01 crore equity shares of face value Rs 10 each and is valid for 45 days from November 12, 2025. The company still needs to submit a listing application and listing agreement before NSE issues the final approval for migration.

Likely market impact

Main Board listing typically improves liquidity, widens investor reach, and boosts visibility, which can support long term valuation for shareholders.